Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
about
Bevacizumab for glioblastomaTwisted tango: brain tumor neurovascular interactionsMedical management of brain tumors and the sequelae of treatment.A randomized trial of bevacizumab for newly diagnosed glioblastomaAngiogenic inhibition in high-grade gliomas: past, present and future.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Chemotherapy-related changes in cognitive functioning.Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.Verbal Learning Processes in Patients with Glioma of the Left and Right Temporal Lobes.Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerReport of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitationsNeurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe GliomaBevacizumab for the treatment of glioblastoma.Neurocognitive functioning in patients with glioma of the left and right temporal lobesNet clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesThe impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.Chemotherapy-related cognitive dysfunction.Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalitiesBevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Current status of antiangiogenic therapies for glioblastomas.Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma.Relationship between cognitive function and prognosis in glioblastoma.Antiangiogenic therapies for glioblastoma.Bevacizumab in recurrent glioblastoma: five informative patient scenarios.Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature.Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.Illness intrusiveness and subjective well-being in patients with glioblastoma.Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials.Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.How treatment monitoring is influencing treatment decisions in glioblastomas.Refining endpoints in brain tumor clinical trials.
P2860
Q26776307-36B22275-4345-4FA5-847B-B872F61085A8Q26849613-9F1796DE-27C2-4F71-8AB1-9B9204CCC203Q26992174-8679DC65-AF5F-4A2D-90E1-7DEB685E4EB9Q30410163-69A7C2B5-7172-4F98-A92A-454E69D7791BQ30455596-39B00578-B598-4372-A487-7C2911DE30DBQ30737224-D56D41DA-BF88-480E-86F4-4D9779B55A10Q33697950-4877C92D-02C4-4BA2-9283-C498F110A9ECQ34234748-02F4273E-6C06-4976-97FD-6B9D8747AE6BQ36477893-413F423A-41D6-4578-AC92-E8578C144993Q36589758-00777FF5-E951-48C0-9514-8EA5F591BFD7Q36625206-0294411A-2EEA-4166-B4DB-9182A1186A8FQ36698172-65C35646-0C5C-4DF2-A254-E2A127BCFE23Q36698177-1711BCF4-F401-4082-A159-FABF06638028Q36797235-C1F0CA76-5E09-4F00-A1E3-4F72AF050C48Q36929502-18D1D36E-5586-4B12-AA0A-872AC8B75FD7Q36944818-194FB7A9-59A5-47CD-979A-5A703879359EQ37278376-042E0D7D-3B95-4F7C-90E9-2DC4D712A7A9Q37278379-42C58701-C129-4B55-9B3F-BEF0ADBE42DDQ37350784-52CE64BD-9996-4968-9ABB-3052CA32E7E0Q37986511-4E91AAEE-FDE1-4472-9829-0982D92948C3Q37997653-9D932F50-FC18-4E8D-A978-6BEAAC3B20F3Q38055317-626A335C-9272-4027-8FB8-7B16006D3479Q38068203-F273B9B5-E2D7-4779-A0F0-BEF0EE8784B9Q38169761-043AD9AA-AC28-4BB8-AD64-DA01BD23291BQ38178105-E7C1542B-31F1-42C8-8BE1-C7FF87A180F5Q38233450-643A5C6D-FEAD-40A7-9E3A-F6E0DD23ADDDQ38264310-D9FC688A-8EB1-4B68-98C7-D1DC01A45F29Q38409696-E120239F-42B7-499E-AA53-8F8E41E65609Q38623875-DA3B3877-9DC7-4B9B-A562-1324AD55DE32Q38779273-C6C787E0-D660-4CC6-99E8-11139B08EC19Q39611554-915C4F31-9712-4B83-B6E5-8DE49BAB595CQ40485578-7FFECF78-4C51-447C-8A1C-1840EA5C9759Q41450286-7D5CCEAA-975F-42F6-B3DD-EE2429E3AACFQ42113451-449CA01B-BAA0-40A1-943E-8C11E9F7F3A3Q42745005-1012A171-D6E4-401E-B909-984BB1E0070DQ46605340-6A5D83FF-BCD8-4303-BF81-F498A84DDA35Q47436703-3D956DDF-CB7A-4EBE-8493-395E14995E72Q47450073-833B428C-8E66-44FF-B813-F36EF61C9A78Q48292017-FE2C081C-AB5C-4CEE-8213-2A34DD984507Q48462987-C06BD55E-4778-4B7A-8678-E6B1090BA01A
P2860
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@ast
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@en
type
label
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@ast
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@en
prefLabel
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@ast
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@en
P2093
P2860
P356
P1433
P1476
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
@en
P2093
David Schiff
James L Zazzali
James Vredenburgh
Jeffrey S Wefel
Lauren E Abrey
Maoxia Zheng
Martin K Nicholas
Michael Prados
Nina Paleologos
P2860
P304
P356
10.1093/NEUONC/NOR024
P577
2011-05-09T00:00:00Z